SCHEMBL15729326

SCHEMBL15729326

Cc1cc(C(F)(F)F)cc(F)c1OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM1A O60341 5/20 0.43
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
PTPN1 P18031 3/20 0.43
PTPN2 P17706 2/20 0.43
PTPN6 P29350 2/20 0.43
TACR1 P25103 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
HTR2B P41595 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
PTGER1 P34995 2/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15729804 0.84 THRA (0.49) KDM1AMAOAMAOBPTPN1PTPN2
SCHEMBL15729343 0.83 KDM1A (0.46) MEN1KMT2AKDM1AMAOAMAOB
SCHEMBL12799710 0.77 KDM1A (0.49) MEN1ALDH1A1KMT2AKDM1AMAOA
SCHEMBL8555303 0.77 KDM1A (0.49) MEN1ALDH1A1KMT2AKDM1AMAOA
SCHEMBL3979117 0.76 NR1H2 (0.46) PTPN1MAPTMAPK1TDP1L3MBTL1
SCHEMBL5020031 0.76 KDM1A (0.54) KDM1AMAOAMAOBPTPN1SLC6A4
SCHEMBL14112773 0.76 MAPT (0.46) MEN1ALDH1A1KMT2AMAOBPTPN1
SCHEMBL13169327 0.76 L3MBTL1 (0.46) MEN1ALDH1A1KMT2AMAOBPTPN1
SCHEMBL18703359 0.75 MRGPRX4 (0.61) HTR2CSLC6A4HTR2BMAPTMAPK1
SCHEMBL31043008 0.75 HTR2C (0.48) PTPN1PTPN2PTPN6TACR1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2921480-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-10-11 EP disclosed
EP-2921480-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-10-11 EP disclosed
US-9777005-B2 Bicyclic heterocyclic compound containing a substituted pyrrole ring TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
US-9777005-B2 Bicyclic heterocyclic compound containing a substituted pyrrole ring TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
US-9732086-B2 2017-08-15 US disclosed
US-9732086-B2 2017-08-15 US disclosed
US-20150307497-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-29 US disclosed
EP-2921480-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-09-23 EP disclosed
WO-2014077401-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2014-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307497-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM2, CHRM4 MEN1 2237/4885ALDH1A1 2232/4885KMT2A 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.